BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Sofosbuvir

First Posted Date: 2014-01-10

Last Posted Date: 2015-10-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 238

Registration Number: NCT02032888

Locations: 🇺🇸
University Gastroenterology, Providence, Rhode Island, United States
🇺🇸
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸
Tarrant County Inf Dis Assoc, Fort Worth, Texas, United States

and more 34 locations

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Sofosbuvir
Drug: Ribavirin

First Posted Date: 2014-01-10

Last Posted Date: 2017-02-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 116

Registration Number: NCT02032875

Locations: 🇺🇸
University Of Miami Schiff Center For Liver Diseases, Miami, Florida, United States
🇺🇸
University Of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸
Baylor St. Luke'S Medical Center, Houston, Texas, United States

and more 2 locations

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

Phase 3

Completed

Conditions: Recurrent Glioblastoma

Interventions: Biological: Nivolumab
Biological: Bevacizumab
Biological: Ipilimumab

First Posted Date: 2013-12-23

Last Posted Date: 2024-07-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 529

Registration Number: NCT02017717

Locations: 🇺🇸
Local Institution - 0055, Los Angeles, California, United States
🇺🇸
Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0008, Baltimore, Maryland, United States

and more 84 locations

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Phase 1

Completed

Conditions: Immunology

Interventions: Drug: [11C]BMT-136088
Drug: BMS-986020

First Posted Date: 2013-12-23

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT02017730

Locations: 🇺🇸
Yale Pet Center, New Haven, Connecticut, United States

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Dasatinib
Drug: Nivolumab

First Posted Date: 2013-12-16

Last Posted Date: 2020-03-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT02011945

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦
QEII Health Sciences Centre-VG Site, Halifax, Nova Scotia, Canada
🇩🇪
Campus Virchow Klinikum Der Charite, Berlin, Germany

and more 10 locations

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Completed

Conditions: NonValvular Atrial Fibrillation

Interventions: Drug: Eliquis

First Posted Date: 2013-12-11

Last Posted Date: 2022-06-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6372

Registration Number: NCT02007655

Locations: 🇯🇵
Local Institution, Toyama-shi, Toyama, Japan

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Asunaprevir
Drug: Daclatasvir

First Posted Date: 2013-11-26

Last Posted Date: 2020-08-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 218

Registration Number: NCT01995266

Locations: 🇨🇳
Local Institution, Tainan, Taiwan

Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: Ipilimumab

First Posted Date: 2013-11-25

Last Posted Date: 2016-03-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01990859

Locations: 🇯🇵
Local Institution, Chuo-shi, Yamanashi, Japan

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Various Advanced Cancer

Interventions: Drug: BMS-986115

First Posted Date: 2013-11-18

Last Posted Date: 2016-09-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT01986218

Locations: 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV/ASV/BMS-791325

First Posted Date: 2013-11-08

Last Posted Date: 2015-11-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 416

Registration Number: NCT01979939

Locations: 🇺🇸
Carolinas Center For Liver Disease, Statesville, North Carolina, United States
🇺🇸
Healthcare Research Consultants, Tulsa, Oklahoma, United States
🇺🇸
Johns Hopkins Medical Institutions, Lutherville, Maryland, United States

and more 41 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy